Synthesis and PET Imaging Biodistribution Studies of Radiolabeled Iododiflunisal, a Transthyretin Tetramer Stabilizer, Candidate Drug for Alzheimer's Disease.
Sameer M JoshiThomas C WilsonZibo LiSean PreshlockVanessa Gómez-VallejoVéronique GouverneurJordi LlopGemma ArsequellPublished in: Molecules (Basel, Switzerland) (2024)
The small-molecule iododiflunisal (IDIF) is a transthyretin (TTR) tetramer stabilizer and acts as a chaperone of the TTR-Amyloid beta interaction. Oral administration of IDIF improves Alzheimer's Disease (AD)-like pathology in mice, although the mechanism of action and pharmacokinetics remain unknown. Radiolabeling IDIF with positron or gamma emitters may aid in the in vivo evaluation of IDIF using non-invasive nuclear imaging techniques. In this work, we report an isotopic exchange reaction to obtain IDIF radiolabeled with 18 F. [ 19 F/ 18 F]exchange reaction over IDIF in dimethyl sulfoxide at 160 °C resulted in the formation of [ 18 F]IDIF in 7 ± 3% radiochemical yield in a 20 min reaction time, with a final radiochemical purity of >99%. Biodistribution studies after intravenous administration of [ 18 F]IDIF in wild-type mice using positron emission tomography (PET) imaging showed capacity to cross the blood-brain barrier (ca. 1% of injected dose per gram of tissue in the brain at t > 10 min post administration), rapid accumulation in the liver, long circulation time, and progressive elimination via urine. Our results open opportunities for future studies in larger animal species or human subjects.
Keyphrases
- pet imaging
- wild type
- positron emission tomography
- small molecule
- computed tomography
- case control
- endothelial cells
- cognitive decline
- high resolution
- multiple sclerosis
- high fat diet induced
- pet ct
- emergency department
- resting state
- high dose
- electron transfer
- insulin resistance
- gram negative
- low dose
- multidrug resistant
- brain injury
- pluripotent stem cells
- cerebral ischemia
- heat stress
- light emitting